You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

Article metrics

Article menu

Download PDFPDF

Treatments
Original article
Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

 

Online download statistics by month:

Online download statistics by month: July 2018 to March 2024

AbstractFullPdf
Jul 201819219267
Aug 2018737322
Sep 2018454525
Oct 2018555622
Nov 2018383826
Dec 2018353526
Jan 2019494523
Feb 2019373617
Mar 2019535031
Apr 2019252511
May 2019383821
Jun 2019424216
Jul 2019434220
Aug 2019444414
Sep 2019232214
Oct 2019363416
Nov 2019262313
Dec 2019292814
Jan 2020151518
Feb 202026269
Mar 2020252414
Apr 202020206
May 202017176
Jun 2020121211
Jul 2020171511
Aug 202015137
Sep 202030236
Oct 202013135
Nov 2020181411
Dec 2020251912
Jan 202115157
Feb 202123224
Mar 202120203
Apr 202122223
May 202128258
Jun 202124235
Jul 202121219
Aug 2021323215
Sep 2021242410
Oct 2021232021
Nov 20217617
Dec 202115149
Jan 202212128
Feb 2022784
Mar 202215157
Apr 202214135
May 202226268
Jun 202230296
Jul 202215121
Aug 202223232
Sep 2022151513
Oct 202219176
Nov 2022272310
Dec 202214148
Jan 2023141217
Feb 202328262
Mar 20231079
Apr 2023141219
May 2023161310
Jun 2023330
Jul 2023654
Aug 2023552
Sep 2023984
Oct 202311102
Nov 202323236
Dec 202357398
Jan 2024886
Feb 202410912
Mar 20241194
Total18121719808